According to the obtained RR of 0.97 [0.92; 1.02] and heterogeneity (I2 = 0%), it was suggested that CP transfusion should not be used outside of randomized trials because this therapy did not improve the survival of COVID-19 patients [47]. The gene discussed is CP; the disease is COVID-19.